CLXN - Has aquired worldwide exclusive Rights to the ThyroTest Pharma.This is a United on the International Pharma Market, and i will bring CLX Medical a Great Great Performances, Big Profit will come $$$$$$ The Share Price of CLXN will we extremely explode.A Big Run will come.
I have more Informtions.his is my Advantage - I will not said it.I will definetly buy more and more of CLXN Stocks, which makes e Rich and othe Investors make rich $$$$$$$$$$$$$$$$$$$$$$$$
CLXN - The $.10 will come.Thats Defenitly correct.Yea. will by more and will catch tommorrow more stocks and by mo9re and more.
I have more Infom´formations too.
In the folling here a actuelle News from 17.09.2008, 23.09.2008, 25.08.2009 and the Interview betwen Q & A and Vera Leonard, CEO of CLXN Medical with futere Targets.The Huge Great Next News will come as soon:
The News from 17.09.2008:
$$$$$$$$$$$$$$$$$$$$$$$$$
CLX Medical, Inc. - CLXN
--------------------------------------------------
CLX Medical, Inc. Files Form 8-K on Definitive Agreement for the Acquisition of the ThyroTest(R) Rapid Screening Device
2008-09-17 10:02 ET - News Release
MURRIETA, CA -- (MARKET WIRE) -- 09/17/08
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, has filed a Current Report on Form 8-K regarding its planned purchase of ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.
The Form 8-K can be accessed through a link to SEC filings in the "Corporate" section of the CLX Medical website, CLX MEDICAL INC..
The Form 8-K reports that on September 9, 2008, CLX Medical entered into a product purchase agreement with ThyroTec, LLC, the developer of the ThyroTest® device, pursuant to which CLX Medical will acquire from ThryoTec the exclusive, worldwide rights to ThyroTest®, together with related packaging and marketing materials. The purchase price for the acquisition consists of a cash payment of $750,000 upon closing and the issuance of Series C convertible preferred stock of CLX Medical convertible into fifteen percent (15%) of the total, fully-diluted common stock of the company.
Upon closing, Jim Small, ThyroTec's chief executive officer, or his designate will be appointed as a member of CLX Medical's board of directors. Mr. Small has 30 years of thyroid related pharmaceutical experience and is the co-founder of ThyroTec.
The News from 23.09.2008:
$$$$$$$$$$$$$$$$$$$$$$$$$
Re: CLX Medical, Inc. Files Form 8-K on Definitive Agreement for the Acquisition of the ThyroTest(R
--------------------------------------------------
Press Release Source: CLX Medical, Inc.
CLX Medical, Inc. Announces Long Term Employment Agreement
with CEO Vera Leonard
Issued Tuesday September 23, 9:36 am ET
MURRIETA, CA--(MARKET WIRE)--Sep. 23, 2008 -- CLX Medical, Inc. (OTC BB:
CLXN), which is focused on the marketing and distribution of unique medical diagnostic
testing products, today announced a three year employment agreement with Chief
Executive Officer Vera Leonard.
Ms. Leonard’s compensation package includes a combination of a base salary, a schedule
of salary increases based on a variety of factors including the company’s revenue and
profit performance, the granting of restricted common stock, medical coverage, and
expense reimbursements. Ms. Leonard’s full employment agreement will be filed as an
exhibit to the company’s annual report for the fiscal year ending September 30, 2008.
The employment contract was executed as CLX prepares to close the acquisition of
ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the
detection of hypothyroidism in adults, a common thyroid disease.
On September 9, 2008, CLX Medical entered into a product purchase agreement with
ThyroTec, LLC, the developer of the ThyroTest® device, pursuant to which CLX
Medical will acquire from ThryoTec the exclusive, worldwide rights to ThyroTest®. In
addition to working to close the transaction, Ms. Leonard and CLX Medical management
is focused on the execution of a post-acquisition marketing and distribution plan for
ThyroTest®.
“I am pleased to have reached agreement on a long term employment agreement with the
CLX Medical board and look forward to the successful implementation of our strategy to
build value for CLX Medical shareholders,” stated Ms. Leonard. “The pending
acquisition of ThyroTest® is expected to be a major milestone in our efforts to establish
value in the company based on revenues from worldwide sales of this device and
additional products that may be distributed in the future.”
Robert McCoy, chairman of CLX Investment Company, commented, “The Board
believes that Ms. Leonard is the right person to implement the marketing and distribution
strategy for ThyroTest®, and the execution of this employment agreement, which ties
increases in her compensation to the revenue and profit performance of CLX Medical, is
the right step for the company at this time. We look forward to seeing the further
development of CLX Medical under her leadership.”
ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be
administered in the more than 100,000 CLIA waived doctor’s offices in the U.S., as well
as in any non-waived laboratory. The simple rapid diagnostic test is a qualitative
measurement that allows physicians to screen adult patients for hypothyroidism in
approximately ten minutes with a whole blood sample.
To sign up to receive information by email directly from CLX Medical, Inc. when new
press releases, investor newsletters, SEC filings, or other information is disclosed, please
visit CLX MEDICAL INC..
About CLX Medical, Inc.
CLX Medical, Inc. (CLX MEDICAL INC.) holds a 51% equity interest in Zonda, Inc.
(Zonda Incorporated - Official Web Site), which has developed several rapid point of care tests for
medical and non-medical markets, including a rapid test for chlamydia. CLX has also
entered into a definitive agreement to acquire ThyroTest®, a rapid thyroid stimulating
hormone (TSH) screening device used for the detection of hypothyroidism in adults, a
common thyroid disease. CLX Medical is focused on the successful worldwide
distribution of these and any additional products it may acquire or license.
All statements included in this release, including statements regarding potential future plans and objectives
of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and
uncertainties, some of which are significant in scope and nature beyond CLX Medical’s control. There can
be no assurance that such statements will prove accurate. Actual results and future events could differ
materially from those anticipated in such statements depending on many factors. Historical results are not
necessarily indicative of future performance.
Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
investors@clxmedical.com
Moderation
Zeitpunkt: 04.10.08 01:49
Aktion: Nutzer-Sperre für immer
Kommentar: Doppel-ID - von GuruJoe1
|
Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.
Zurück geht es hier.
Thread abonnieren
